Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Borderline Personality Disorder
NCT03395314Phase 2Terminated
- Sponsor
- Yale University
- Start
- Feb 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in borderline personality disorder (BPD), sponsored by Yale University. Started Feb 2018; status: terminated.
02
Drugs
ketamine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT03395314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395314.